Literature DB >> 16736241

Methylphenidate exerts no neurotoxic, but neuroprotective effects in vitro.

A G Ludolph1, U Schaz, A Storch, S Liebau, J M Fegert, T M Boeckers.   

Abstract

Methylphenidate (MPH) is the most common used drug in child and adolescent psychiatry. Despite of this fact, however, little is known about its exact pharmacological mechanisms. Here we investigated the toxic effects of MPH in vitro in human embryonic kidney (HEK-293) cells stably expressing the human dopamine transporter (HEK-hDAT cells) and in cultured rat embryonic (E14.5) mesencephalic cultures. MPH alone (up to 1 mM) affected neither the growth of HEK-hDAT cells nor the survival of dopaminergic (DA) neurons in primary cultures after treatment up to 72 h. No differences in neuronal arborisation or in the density of synapses were detected. 1-methyl-4-phenylpyridinium (MPP(+)) showed no toxic effect in HEK-293 cells, but had significant toxic effects in HEK-hDAT cells and DA neurons. MPH (1 microM - 1 mM) dose-dependently reduced this cytotoxicity in HEK-hDAT cells and primary mesencephalic DA neurons. The presented results show that application of MPH alone does not have any toxic effect on DA cells in vitro. The neurotoxic effects of MPP(+) could be significantly reduced by co-application of MPH, an effect that is most likely explained by MPH blocking the DAT.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16736241     DOI: 10.1007/s00702-006-0487-5

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  32 in total

1.  Comparative aspects of the brain growth spurt.

Authors:  J Dobbing; J Sands
Journal:  Early Hum Dev       Date:  1979-03       Impact factor: 2.079

2.  Selective dopaminergic neurotoxicity of isoquinoline derivatives related to Parkinson's disease: studies using heterologous expression systems of the dopamine transporter.

Authors:  Alexander Storch; Stefanie Ott; Yu I Hwang; Rainer Ortmann; Andreas Hein; Stefan Frenzel; Kazuo Matsubara; Shigeru Ohta; Hans Uwe Wolf; Johannes Schwarz
Journal:  Biochem Pharmacol       Date:  2002-03-01       Impact factor: 5.858

Review 3.  The functioning neuronal transporter for dopamine: kinetic mechanisms and effects of amphetamines, cocaine and methylphenidate.

Authors:  James O Schenk
Journal:  Prog Drug Res       Date:  2002

4.  Children's persistence with methylphenidate therapy: a population-based study.

Authors:  Anton R Miller; Christopher E Lalonde; Kimberlyn M McGrail
Journal:  Can J Psychiatry       Date:  2004-11       Impact factor: 4.356

5.  Protective effects of riluzole on dopamine neurons: involvement of oxidative stress and cellular energy metabolism.

Authors:  A Storch; K Burkhardt; A C Ludolph; J Schwarz
Journal:  J Neurochem       Date:  2000-12       Impact factor: 5.372

6.  Trends in the prescribing of psychotropic medications to preschoolers.

Authors:  J M Zito; D J Safer; S dosReis; J F Gardner; M Boles; F Lynch
Journal:  JAMA       Date:  2000-02-23       Impact factor: 56.272

Review 7.  Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration.

Authors:  A Storch; A C Ludolph; J Schwarz
Journal:  J Neural Transm (Vienna)       Date:  2004-10       Impact factor: 3.575

8.  Methylphenidate treatment during pre- and periadolescence alters behavioral responses to emotional stimuli at adulthood.

Authors:  Carlos A Bolaños; Michel Barrot; Olivier Berton; Deanna Wallace-Black; Eric J Nestler
Journal:  Biol Psychiatry       Date:  2003-12-15       Impact factor: 13.382

9.  Differential psychostimulant-induced activation of neural circuits in dopamine transporter knockout and wild type mice.

Authors:  J V Trinh; D L Nehrenberg; J P R Jacobsen; M G Caron; W C Wetsel
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

Review 10.  MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease.

Authors:  M Gerlach; P Riederer; H Przuntek; M B Youdim
Journal:  Eur J Pharmacol       Date:  1991-12-12       Impact factor: 4.432

View more
  7 in total

1.  Impact of psychostimulants and atomoxetine on the expression of 8-hydroxyguanine glycosylase 1 in human cells.

Authors:  Andreas Johannes Schmidt; Hans-Willi Clement; Stefan Gebhardt; Ulrich Michael Hemmeter; Eberhard Schulz; Jürgen-Christian Krieg; Tilo Kircher; Philip Heiser
Journal:  J Neural Transm (Vienna)       Date:  2010-05-14       Impact factor: 3.575

2.  Acute and sub-chronic functional neurotoxicity of methylphenidate on neural networks in vitro.

Authors:  K V Gopal; B R Miller; G W Gross
Journal:  J Neural Transm (Vienna)       Date:  2007-06-18       Impact factor: 3.575

3.  The effect of methylphenidate intake on brain structure in adults with ADHD in a placebo-controlled randomized trial.

Authors:  Ludger Tebartz van Elst; Simon Maier; Stefan Klöppel; Erika Graf; Carola Killius; Marthe Rump; Esther Sobanski; Dieter Ebert; Mathias Berger; Andreas Warnke; Swantje Matthies; Evgeniy Perlov; Alexandra Philipsen
Journal:  J Psychiatry Neurosci       Date:  2016-10       Impact factor: 6.186

Review 4.  In vitro study methodologies to investigate genetic aspects and effects of drugs used in attention-deficit hyperactivity disorder.

Authors:  Edna Grünblatt; Jasmin Bartl; Zoya Marinova; Susanne Walitza
Journal:  J Neural Transm (Vienna)       Date:  2012-07-26       Impact factor: 3.575

5.  3,4-Methylenedioxy-N-methamphetamine (ecstasy) promotes the survival of fetal dopamine neurons in culture.

Authors:  Jack W Lipton; Emeline G Tolod; Valerie B Thompson; Lin Pei; Katrina L Paumier; Brian T Terpstra; Kaari A Lynch; Timothy J Collier; Caryl E Sortwell
Journal:  Neuropharmacology       Date:  2008-07-04       Impact factor: 5.250

Review 6.  Stimulant Induced Movement Disorders in Attention Deficit Hyperactivity Disorder.

Authors:  Seok-Hyun Nam; Myung Ho Lim; Tae Won Park
Journal:  Soa Chongsonyon Chongsin Uihak       Date:  2022-04-01

7.  Neuropharmacological mechanisms underlying the neuroprotective effects of methylphenidate.

Authors:  T J Volz
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.